



# Making Visible the Quality of Care for People Living with NCDs

Thursday 20 April 2023 15:00 - 16:15 CEST





**SECTION 1** 

# Welcome and Agenda

Alison Cox







## **Objectives of the Webinar**

- Summarise existing NCD targets and indicators relating to secondary prevention and care provision as laid out by Sustainable Development Goals (including within the context of Universal Health Coverage) and Global Action Plan on NCDs.
- Lay out WHO's upcoming plans to expand facility-based patient and programme monitoring for NCDs.
- Provide civil society a space to reflect on potential next steps to improve global data availability, and corresponding accountability of, NCD care provision.

## SECTION 1 Agenda

#### Welcome

• Scene setting Alison Cox, NCD Alliance

### Current status of NCD care targets and WHO's facility based monitoring work

NCD care targets: current status

Dr Chantelle Boudreaux, Center for Integration Science in Global Health

Delivery Division of Global Health Equity Brigham and Women's Hospital

WHO's work on NCD facility-based monitoring 
Dr Farshad Farzadfar, World Health Organization

Discussion

### NCD Alliance Members/Partners perspectives

Ghana NCDA Presentation Labram Musah Massawudu, National Coordinator, Ghana NCD Alliance

Association (CISC)

WSO Presentation
 Dr Sheila Martins, President, World Stroke Organization

Discussion

### Wrap up

Concluding remarks and next steps
 Alison Cox, NCD Alliance



**SECTION 2** 

Current status of NCD care targets and WHO's facility based monitoring work

Dr Chantelle Boudreaux Dr Farshad Farzadfar







## SDGs


## **CURRENT STATUS OF NCD TARGETS**


MAKING VISIBLE THE QUALITY OF CARE AVAILABLE FOR PEOPLE LIVING WITH NCDS

**NCD Alliance Webinar Series** 

April 20, 2024

### **Chantelle Boudreaux**





# Core Global Commitments

## 2013-2030

NCD Global Action Plan + Global Monitoring Framework

- Support the UNGA HLM overriding goal; 9 targets and 25 indicators
- Original timeline (2013–2020) extended by WHA to align with SDGs

## 2019-2023

WHO's 13th General Program of Work (GPW)

Triple Billion initiative includes universal health coverage


## UN General Assembly High Level Meeting on NCDS

- Establishes focus on 4 major conditions and 4 risk factors. "4x4"
- Authorizes WHO to lead progress. 8 months later, WHA approves "25 by 25"

## Sustainable Development Goals, Agenda 2030

- · Health and well-being is focus of SDG 3
- Specific population-related targets underpinned by 3.8, call for Universal Health Coverage

2015








## Overview of Global Targets: Global Monitoring Framework + SDGs





## **Behavioral Risk Factors**

GMF: 10% relative reduction in harmful use of alcohol

GMF: 10% relative reduction in prevalence of insufficient physical activity

GMF: 30% reduction in population salt intake

GMF: 30% relative reduction in prevalence of tobacco use

GMF: Additional indicators not mapped to targets

Total alcohol per Heavy episodic capita, age 15+

drinking

Alcohol-related morbidity and mortality

Insufficient activity, adolescents

Insufficient activity, adults Age-standardized salt intake

Current tobacco use, adolescents Age-standardized tobacco use, age 18+

Energy from saturated fatty acids, age 18+

<5 servings fruit and vegetables. aged 18+

Policies to limit fatty acids and hydrogenated

Policies to reduce marketing foods. beverages, child

### **Progress against targets**

## **Service readiness**

Data limitations have hindered efforts to monitor the coverage of essential medicines. As of 2020, there was insufficient data on performance against 3.b.3 to calculate estimates for any of the WHO regions, despite covering the period from 2011 through 2019, using nearly a decade's worth of data. In a survey of 25 countries:

#### 28 Percent of countries



No facility stocked all medicines

Country with highest score



More than 30% of facilities lack full set of medicines



#### **GMF Target 9**

80% availability of the affordable basic technologies and essential medicines,




#### SDG 3.b.3

Proportion of health facilities that have a core set of relevant essential medicines available and affordable on a sustainable basis

Includes 32 tracer indicators for acute and chronic communicable and noncommunicable disease for primary care






GMF Target 8: Cover half of eligible people with drug therapy to prevent heart attack and stroke Progress against targets

# Service coverage

Progress is off-track and correlated with income. No low income country met GAP Target 8 in 2019, compared to 60% fo high income countries.



SDG/Global Program of Work Target: 1 billion more people coveted by UHC by 2023



## Service Coverage Index



## O1 Reproductive, Maternal, Neontal and Child Health

- Family planning: Percentage of women of reproductive age (15-49 years) who are married or in-union who have their need for family planning satisfied with modern methods
- Pregnancy and delivery care: Percentage of women aged 15-49 years with a live birth in a given time period who received antenatal care four or more times
- Child immunization:
   Percentage of infants
   receiving three doses of
   diphtheria-tetanus-pertussis
   containing vaccine
- Child treatment: Percentage of children under 5 years of age with suspected pneumonia in the two weeks preceding the survey taken to an appropriate health facility or provider

## 02 Infectious diseases

- Tuberculosis: Percentage of incident TB cases that are detected and successfully treated
- HIV/AIDS: Percentage of people living with HIV currently receiving antiretroviral therapy
- Malaria: Percentage of population in malariaendemic areas who slept under an insecticide-treated net the previous night [only for countries with high malaria burden]
- Water and sanitation:
   Percentage of households
   using at least basic sanitation
   facilities

## 03 Noncommunicable disease

- Hypertension: Agestandardized prevalence of non-raised blood pressure (140/90) among adults aged 18 and older
- Diabetes: Age-standardized mean fasting plasma glucose for adults aged 18 and older
- Tobacco: Age-standardized prevalence of adults >=15 years not smoking tobacco in last 30 days

## 34 Sevice capacity and access

- Hospital access: Hospital beds per capita, relative to maximum threshold of 18/10,000
- Health workforce: Health professionals (physicians, psychiatrict and surgeons) per capita, relative to maximum thresholds
- Health security: International Health Regulations (IHR) core capacity index

## 1 Improve monitoring

- Link investments in care to improved data systems;e.g.
   Facility-Based Patient Programme monitoring initiative
- Push for iterative improvements and disaggregation over time

## 03 Update tracer indices

- Align NCD indicators with RMNCH and Infectious disease indicators
- Document a more diverse array of inputs with a sharper focus on the continuum of care

### 2 Link to other efforts

- Include reference to Appendix 3 of the NCD GAP
- Leverage monitoring for disease specific initiatives and programs (90-70-90 targets for Cervical Cancer; Global HEARTS)

### Opportunities to strengthen indicators

# 4 structural improvements

## 04 Apply an equity lens

- Include all-cause morbidty and mortality
- Incorporate a focus on severe disease

## Example: SCI Indicator selection

- Percent of people with blood pressure > 140/90 on treatment
- Percent of people with Type 1 Diabetes who have access to insulin and blood glucose self monitoring
- Percent of women with identified cervical cancer lesions who are treated



## Thank you

#### Contact

cboudreaux@bwh.harvard.edu




https://centerforintegrationscience.org

Progress against targets

# Premature mortality

Progress generally stuttering. High income countries generally achieve 30% decline in premature mortality, low income countries have acheived less than half that. Targets to reduce hypertension and diabetes are off track.



30 Percent Relative Reduction of Premature Mortality



Global reduction in premature mortality fell from 22.9% in 2000 to 17.8% in 2019. Driven by gains in high income regions



Pace of decine would need to nearly triple to meet target



Gaps in current targets

# 3 major categories





SCI Indicator selection

Gap 2



Data availability
Gap 3

- Mortality target: Age and disease focus excludes much of the disease burden.
- Health systems targets: primary prevention / care focus omits care continuum
- Contrast with other disease groups
- Fails to measure effective coverage or unmet need;
- · Fails to measure diseases continuum;
- Carried forward through multiple monitoring frameworks
- Limits transparency and undermines accountability
- Obscures important inter- and intracountry variations in risk and epidemiology of NCDs



## **NCD** facility-based monitoring

Dr. Farshad Farzadfar

Scientist Surveillance, Monitoring, and Reporting NCD department, WHO






## IMPLEMENTATION ROADMAP 2023–2030 FOR THE GLOBAL ACTION PLAN FOR THE PREVENTION AND CONTROL OF NCDs 2013–2030

• Strategic Directions

- 1. Accelerate national response based on the understanding of NCDs epidemiology and risk factors and the identified barriers and enablers in countries
- 2. Prioritize and scale-up the implementation of most impactful and feasible interventions in the national context
- 3. Ensure timely, reliable and sustained national data on NCD risk factors, diseases and mortality for data driven actions and to strengthen accountability

## NCD surveillance system components





## Facility-based patient and program monitoring in primary care

- Supporting health facility managers to ensure NCDs core medications availability at the facility level
- Supporting health facility managers to ensure technology availability (lab testing/functional equipment) at the facility level
- Supporting health facility and higher levels managers/authorities to ensure accessibility/utilization of healthcare
- Supporting health professionals and managers at the facility/district/national levels to evaluate the outcome of provided services





Noncommunicable disease facility-based guidance:

scope and development process

Comprehensive monitoring for essential noncommunicable disease interventions at primary care settings

- oCardiovascular diseases including hypertension
- ODiabetes
- OAsthma and chronic obstructive pulmonary disease
- OBreast cancer, cervical cancer, childhood cancers and general cancers

Rigorous development and prioritization processes (experts' opinions, systematic reviews, global and regional priorities)


















Noncommunicable disease facility-based guidance:

monitoring domains and indicators

Domains aligned with WHO primary health care measurement framework and indicators: monitoring health systems through a primary health care lens

- •Programme determinants (health system capacity and management)
- OService delivery (early detection and diagnosis, treatment and complication assessment)
- oProgramme objectives (disease control)


A total of 22 core indicators and 59 optional indicators, organized by results chain framework, NCDs and monitoring domains





## Noncommunicable disease facilitybased monitoring guidance

- Background, Introduction
- Noncommunicable disease facility-based monitoring guidance (Framework)
- List of core and optional indicators and their metadata
- Application of the Noncommunicable disease facilitybased monitoring guidance in country health facilitybased monitoring systems





Facilitybased patient and program monitoring framework









#### **PROGRAMME OBJECTIVES**

#### INPUTS/PROCESSES OUTPUTS

INPUTS/PROCESSES

#### System capacity and management

System capacity and management

Availability of diabetes core medicines

Availability of plasma glucose testing

Availability of Hemoglobin A1c testing

- Availability of hypertension core medicines Availability of cardiovascular disease core
- Availability of a functional blood pressure measuring device

#### Early detection and diagnosis

- Assessment of cardiovascular disease risk
- (aged ≥40 years) Screening for hypertension among adults as
- part of routine service Hypertension detection from opportunistic screening

#### Complication assessment

Assessment for chronic kidney disease among

#### OUTCOMES

#### Disease control

- Blood pressure control among people with hypertension
- Blood pressure control among people with hypertension (follow-up)

Glycaemic control among people with diabetes

Chronic kidney disease among people with

Lower-limb amputation among people with

Glycaemic control among people with diabetes

people newly diagnosed with hypertension

#### DIABETES

#### **OUTPUTS**

#### Treatment

- Pharmacological treatment among people
- with diabetes Statin therapy among people with diabetes
- Pharmacological treatment for chronic kidney
- disease among people with diabetes Pharmacological treatment for hypertension

#### Complication assessment

among people with diabetes

- Assessment for diabetic chronic kidney
- Assessment for diabetic foot among people
- Referral for retinopathy screening among

#### diabetes diabetes Blindness among people with diabetes

OUTCOMES

Disease control

(follow-up)

- disease among people with diabetes

- with diabetes
- people with diabetes

#### ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE

#### INPUTS/PROCESSES

#### System capacity and management

- Availability of asthma core medicines
- Availability of chronic obstructive pulmonary disease core medicines
- Availability of peak flow meter and mouthpiece

#### OUTPUTS

#### Early detection and diagnosis

- Asthma diagnosis using peak flow measurement Chronic obstructive pulmonary disease
- diagnosis using peak flow measurement

#### Treatment

- Treatment among people with asthma
  - Treatment among people with chronic obstructive pulmonary disease

#### OUTCOMES

#### Disease control

- Asthma control Chronic obstructive pulmonary disease control
- Emergency visit among people with asthma
- Emergency visit among people with chronic obstructive pulmonary disease

#### **BREAST CANCER**

#### INPUTS/PROCESSES

#### System capacity and management

#### OUTPUTS

#### Early detection and diagnosis

- Clinical breast evaluation for early diagnosis of breast cancer among women aged 30-49
- years with signs and/or symptoms associated with breast cancer Timeliness of referral for breast cancer
- diagnosis among women aged 30-49 years with associated signs and/or symptoms of breast cancer who had suspicious findings from clinical breast evaluation
- Referral for mammography screening among women aged 50-69 years
- Timeliness of breast cancer confirmatory diagnosis among women aged 30-49 years with suspicious findings from clinical breast evaluation

#### Treatment


Timeliness of breast cancer treatment among women aged 30-49 years with suspicious findings from clinical breast evaluation



#### OUTCOMES

#### Disease control

Facilitybased patient and program monitoring framework (2)









	CERVICAL CANCER	
INPUTS/PROCESSES	OUTPUTS	OUTCOMES
System capacity and management	Early detection and diagnosis	Disease control
Availability of human papillomavirus testing     Availability of Pap smear testing     Availability of visual inspection with acetic acid testing	Cervical cancer screening with high performance test among women aged 30–49 years Cervical cancer screening among women aged 30–49 years Cervical cancer screening test positivity among women aged 30–49 years Cervical cancer rescreening among women aged 30–49 years	
	Treatment	
	Pre-invasive cervical disease treatment among women aged 30–49 years     Timeliness of referral for cervical cancer diagnosis among women aged 30–49 years with suspicious findings from cervical cancer screening	
	CHILDHOOD CANCER	
INPUTS/PROCESSES	OUTPUTS	OUTCOMES
System capacity and management	Early detection and diagnosis	Disease control
	<ul> <li>Clinical evaluation for early diagnosis of childhood cancer among children with signs and/ or symptoms associated with childhood cancer</li> <li>Timeliness of referral for childhood cancer diagnosis among children with associated signs and/or symptoms of childhood cancer who had suspicious findings from clinical evaluation</li> </ul>	
	GENERAL CANCERS	
INPUTS/PROCESSES	OUTPUTS	OUTCOMES
System capacity and management	Early detection and diagnosis	Disease control
	<ul> <li>Clinical evaluation for early diagnosis of cancer among people with signs and/or symptoms associated with cancer</li> </ul>	
	<ul> <li>Timeliness of referral for cancer diagnosis among people with associated signs and/or symptoms of cancer who had suspicious findings from clinical evaluation</li> </ul>	
	CROSS-CUTTING	
INPUTS/PROCESSES	OUTPUTS	OUTCOMES
System capacity and management	Early detection and diagnosis	Disease control
<ul> <li>Availability of trained staff</li> <li>Completeness and timeliness of reporting by health facilities</li> <li>Facilities receiving supervisory visit</li> </ul>	Loss to follow-up  Treatment	
. demois receiving supervisory visit	<ul> <li>Loss to follow-up</li> <li>Complication assessment</li> </ul>	
	Loss to follow-up	



## Indicator metadata

- Definition, purpose, numerator, denominator, calculation method, aggregation, disaggregation, sources of data, key data elements, frequency of reporting, users of data, limitations/comments and related links
- Comparability of data across geographical areas and across times



C2-Availability of plasma glucose testing

Indicator name	Availability of plasma glucose testing	
Purpose	To ensure uninterrupted services to diagnose diabetes and assess glycemic control among patients with diabetes	
Definition	Proportion of health facilities that have capability of laboratory or point of care plasma glucose (PG) testing	
Numerator	Number of health facilities reporting capability of performing either laboratory or point of care PG tests in the reporting period	
Denominator	Total number of health facilities	
Method of calculation	Numerator ÷ denominator × 100	
Aggregation	District, province, state, national	
Disaggregation	Health facility, provider ownership type (public/private), facility location type (urban/rural), plasma glucose testing site (point-of-care or laboratory)	
Sources of data	Health facility reports, regional logistics information system or survey	
Key data elements	Count of number of facilities reporting "test capability"	
Frequency of reporting	Quarterly	
Users of data	District-, province- and state-level managers to focus supervision on health facilities reporting no lab capability, making facilities capable and strengthening health systems to ensure uninterrupted laboratory services	
Limitations/ comments	In some settings the health facilities do not provide laboratory service so the reporting units will need to come from other laboratory service providers	
Related links	Harmonized health facility assessment (HHFA): core questions https://www.who.int/publications/i/item/harmonized-health-facility-assessment-(hhfa)	

Data collection and interpretation tools

Paper-based tool

DHIS2 Aggregate (program monitoring)

DHIS2 tracker (patient and program monitoring)

E-registry (patient management, patient and program monitoring)






Next steps to complete health service delivery monitoring

tools Secondary and tertiary level facilitybased patient and program monitoring

- Facility level survey on service readiness, availability, utilization, and outcome tool
- Patient reported outcome measures (community level) tool
- Target setting and action plan developer tool





## Concerns and challenges

- Standards
- Infrastructure
- Capacity building
- Data for action (service management system)
- Data quality
- Fragmentation















## Thanks!

Do you have any questions?

farzadfarf@who.int





**SECTION 2** 

## **Discussion**

- Have these gaps in global reporting on NCD care had any impact on implementation of NCD prevention and care programmes at national level?
- Any initial reflections on the work WHO is undertaking on NCD facility-based monitoring or on how your organisations could support its roll out?





THEMATIC WEBINAR SERIES

**SECTION 3** 

NCD Alliance Members/Partners Perspectives

Labram Musah Massawudu Dr Yasjudan Putra Dr Sheila Martins







Yasjudan Putra, M.D

Presented at the 2023 NCD Alliance Webinar Series

UNIVERSITAS GADJAH MADA




- Name : Yasjudan Rastrama Putra
- Institusion:
  - Gadjah Mada University (Lecturer/ Reseacher)
  - Sardjito General Hospital (Internist/ Hematology-Medical Oncology Fellow)
- Research Partner : CISC (Cancer Information & Support Center) Indonesia



## 1.3 A Long Journey to Jaminan Kesehatan Nasional (JKN)



TI



Workers in the formal Sector

(ex-ASKES, ASABRI, JPK-

JAMSOSTEK)

**Wage Recipents** 



"Missing middle" (neither poor nor employed in the formal economy) Non- Wage Recipents Retires & Veterans

Low Income (ex-Jamkesmas)

Non-Contributing Members


## Patient community initiative for data collection



- Training on the importance of data from UICC → CISC took the initiative to invite the Center for Health Policy and Management at Gadjah Mada University to conduct research.
- HER2+ breast cancer research
  - Quantitative research: 100 patient community members
  - Qualitative research: 18 doctors in oncology (medical, surgical, radiation, pathology)









- Early detection : The policy already exists but needs to be strengthened
- Diagnosis: Equal distribution of facilities and human resources
- Therapy: Lack of a multidisciplinary team approach. Based on the UHC, Trastuzumab is not available at an early stage
- Recurrence: Early diagnosis and standard therapy are needed
- Socioeconomic impact : The amount of costs excluding hospital fees

# Impact → Policy advocacy



 Dissemination of research results: Researcher, Patient community, MoH, UHC management

• Policy brief: 98%

Publication : hopefully soon



Diseminasi Perjalanan Pengobatan dan Kekambuhan pada Penyintas Kanker Payudara HER-2 Positif

363 x ditonton • Streaming 2 bulan yang lalu



PKMK FK-KMK UGM

Diseminasi Perjalanan Pengobatan dan Kekambuhan pada Penyintas Kanker Payudara HER-2 Positif 00:00:05 Pembukaan MC ...



Pembukaan MC | Sambutan: Aryanthi Baramuli Putri, SH.,MH (CISC) | Pemaparan: dr. Yasjudan...

7 momen V



# Reflections at the global level



The patient community has an important role









Data-driven advocacy





# Overview of WSO's work to support data collection Opportunities and challenges for expanding

Sheila Cristina Ouriques Martins President World Stroke Organization


#### **Stroke in numbers**




#### 101 MILLION

people worldwide are living with stroke aftermath

THIS NUMBER HAS ALMOST DOUBLED OVER THE LAST 30 YEARS



1 in 4 people will have a stroke in their lifetime
THIS NUMBER HAS
INCREASED 50%OVER
THE LAST 17 YEARS



# We know what need to be implemented

AAS 48h

**Stroke Unit** 

Thrombolysis 4.5h

Hemicraniectomy 48h malignant MCA infarction

**Thrombectomy 24h LVO** 

DAPT in TIA/Mild Stroke 24h





• To know the situation of stroke services on global level is fundamental

• To monitor the quality and the outcomes of the programs we need to

monitor data



### The state of stroke services across the globe: Report of World Stroke Organization-World Health Organization surveys

International Journal of Stroke 0(0) 1–13
© 2021 World Stroke Organization Article reuse guidelines: sagepub.com/journals-permissions DOI: 10.1177/17474930211019568 journals.sagepub.com/home/wso

**\$**SAGE

Mayowa O Owolabi<sup>1</sup>, Amanda G Thrift<sup>2</sup>, Sheila Martins<sup>3</sup>, Walter Johnson<sup>4</sup>, Jeyaraj Pandian<sup>5</sup>, Foad Abd-Allah<sup>6</sup>, Cherian Varghese<sup>7</sup>, Ajay Mahal<sup>8</sup>, Joseph Yaria<sup>9</sup>, Hoang T Phan<sup>10</sup>, Gregory Roth<sup>11</sup>, Seana L Gall<sup>10</sup>, Richard Beare<sup>12</sup>, Thanh G Phan<sup>13</sup>, Robert Mikulik<sup>14</sup>, Bo Norrving<sup>15</sup> and Valery L Feigin<sup>16</sup>; on behalf of the Stroke Experts Collaboration Group\*

#### **Stroke Services Across the Globe**

- 84 countries, 318 hospitals
- SU were present in 91% of HIC in contrast to 18% of LIC (p< 0.001)</li>
- Acute stroke treatments were offered in 60% of HIC compared to 26% of LIC (p = 0.009)
- Only 50% of countries reported at least 50% of all the recommended elements for acute care, with most in HICs and upper-MICs




35% minimun required structure of a stroke center


- Advanced Essential
- Minimal


# Improving access to quality stroke care the WSO online Roadmap











#### **WSO Roadmap Online Platform**



Minimal	Criteria for classification as Essencial Center	
#ID	Criterion	Status
#94	Does your hospital have emergency services?	ок
#95	If there is an emergency department, is it open 24h a day, 7 days a week?	ОК
#96	CT scanner  Does your hospital have CT scanner?	ок
#30	Computed Tomography 24/7 Computed Tomography (CT) brain scan in the hospital (on site) available 24 hours/day, 7 days/week	ок
#97	Does your hospital have its own laboratory for blood tests?	ок
#7	Laboratory blood test 24/7 Complete blood count, electrolytes, urea, glucose, INR, PT available 24 hours a day, 7 days a week?	ок
#115	Physicians for thrombolysis  Access to physicians with training in acute stroke care available for thrombolysis (can be through telemedicine)	Not met
#98	IV thrombolysis Access to IV thrombolysis	Not met
#20	Thrombolysis 24/7 Access to fV thrombolysis 24h/day, 7days/week	Not met

# **Angels Initiative**





> 105,000 registered doctors and nurses


> 7,200 Hospitals 147 Countries

### Implementation of Quality Monitoring

• Hospitals who capture data in either the **RES-Q Registry**, **SITS QR** Registry using the Angels Awards Protocol or an approved National Registry are eligible for an award. Awards are based on the ESO quality measures.










24 Parameter

7 KPIs


**Awards** 

## **WSO & ESO Angels Awards**





#### **About RES-Q**



RES-Q database as on 18<sup>th</sup> April 2023

#### EU Horizon Grant for RES-Q+

Nov 2022-Sept 2026




Revolutionize quality improvement in stroke and provide unique solutions for research, clinical practice and policy making in Europe and beyond

#### **Data extraction**

#### Medical records: discharge summary Anonymization. data extraction tool, NLP More patients Healthcare receive correct better treatment organized Virtual assistant providing feedback, Al

#### Life after stroke diagnosis





ABOUT V

**HOW TO APPLY** 

**CRITERIA** 

**EDUCATIONAL TOOLS** 

SELF-ASSESSMENT





#### **Certificate your hospital**

The certification of stroke centers is critical to ensure the implementation of all high-priority strategies which change the natural history of stroke. It is a great opportunity for continuous improvement and qualification of services.

**Certification Guide** 

**More information** 

**Benefits for certified Centers** 

#### Participating countries



Organização

Colaboradores































Registro do paciente na UBS/SES/SUS *	Idade do paciente *	Sexo do paciente *		
negistic do paciente na 020,020,000	47	anos	1. Masculino	2. Feminino
	47	dilos	i. Mascaino	2.7 (111111110)
Histórico Patológico Prévio				
Hipertensão arterial (HAS) *	Infarto agudo do miocárdio (IAM) *			
0. Não 1. Sim		0. Não   1. Sim		
Doença arterial coronariana (DAC) *		Fibrilação atrial (FA) *		
0. Não 1. Sim		0. Não 1. Sim		
Acidente vascular cerebral (AVC) *	Doença renal crônica (DRC) *			
0. Não 1. Sim	0. Não			
Dislipidemia (DLP) *	Obesidade *			
0. Não		0. Não 1. Sim		
Tabagismo *	Diabetes mellitus (DM) *			
0. Não 1. Sim		0. Não 1. Sim		


Dashboard


1361 patients Mean age 64yo






16% AVC ou IAM prévios





#### **Dashboard**







**SECTION 3** 

# **Discussion**

 What are concrete opportunities to call for improved global reporting on provision of NCD care within the context of the upcoming UNHLM on UHC?





THEMATIC WEBINAR SERIES

**SECTION 4** 

# Wrap up

Alison Cox






#### **SECTION 4**

#### **Next steps**

- Send actionable next steps and ideas to gdubois@ncdalliance.org
- Follow up through PLAN on an Inclusive NCD Agenda for members and by email for Partners

Recording and slides from this thematic webinar will be shared by email and uploaded to NCDA webinar repository.



# THANKS

**THEMATIC WEBINAR SERIES** 

**NCD Alliance** 

www.ncdalliance.org @NCD Alliance



